S. Davidi

176 Evaluating the safety of tumor treating fields (TTFields) application to the torso – in vivo studies

Y. Palti, U. Weinberg, M. Giladi, 2020, Journal for ImmunoTherapy of Cancer.

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo

Y. Palti, U. Weinberg, M. Giladi, 2022, Cancers.

Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.

R. Schneiderman, Y. Palti, U. Weinberg, 2021, Lung cancer.

In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso

Y. Palti, U. Weinberg, Z. Bomzon, 2021, Frontiers in Oncology.

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

E. Kirson, A. Itzhaki, R. Schneiderman, 2020, Cancer Immunology, Immunotherapy.

The antiangiogenic role of the pro-inflammatory cytokine interleukin-31

Y. Shaked, D. Hershkovitz, N. Karin, 2017, Oncotarget.

Anti-VEGF-A Affects the Angiogenic Properties of Tumor-Derived Microparticles

V. Miller, Y. Shaked, S. Scherer, 2014, PloS one.